Mesenchymal Stem/Stromal Cells: UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCS) ISOLATED WITH AN AUTOMATED PROTOCOL STIMULATE THE EXPANSION OF REGULATORY T CELLS (TREGS) VI... von Jurczuk, V., Hernandez, S., Portocarrero, C., Martinez, G., Pyron, L., Umland, O., Xu, X., LoRusso, E.M., Rodriguez, R.U., Ricordi, C., Lanzoni, G.

Volltext

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial von Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., Harter, P.

Volltext

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors von Italiano, A., Infante, J.R., Shapiro, G.I., Moore, K.N., LoRusso, P.M., Hamilton, E., Cousin, S., Toulmonde, M., Postel-Vinay, S., Tolaney, S., Blackwood, E.M., Mahrus, S., Peale, F.V., Lu, X., Moein, A., Epler, J., DuPree, K., Tagen, M., Murray, E.R., Schutzman, J.L., Lauchle, J.O., Hollebecque, A., Soria, J.-C.

Volltext

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial von Harter, P., Marth, C., Mouret-Reynier, M.-A., Cropet, C., Lorusso, D., Guerra-Alía, E.M., Matsumoto, T., Vergote, I., Colombo, N., Mäenpää, J., Lebreton, C., de Gregorio, N., Mosconi, A.M., Rubio-Pérez, M.J., Bourgeois, H., Fasching, P.A., Cecere, S.C., Hardy-Bessard, A.-C., Denschlag, D., de Percin, S., Hanker, L., Favier, L., Bauerschlag, D., Desauw, C., Hillemanns, P., Largillier, R., Sehouli, J., Grenier, J., Pujade-Lauraine, E., Ray-Coquard, I.

Volltext

749P Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelia... von Martin, L.P., Uyar, D., Madariaga, A., Spira, A.I., Oaknin, A., Schilder, R., Alia, E.M. Guerra, Hamilton, E.P., Naumann, R.W., Lorusso, D., Lu, L., Berman, C.J., Borgman, A.E., Moroney, J.W.

Volltext

1669P Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes von Medina, J.E., Roussos Torres, E.T., Leal, A., Adleff, V., Lumbard, K., Keefer, L., Carey, J., Brufsky, A., Lorusso, P., Eder, J.P., Chung, V., Downs, M., O'Connor, A., Piekarz, R., Streicher, H., Jaffee, E.M., Scharpf, R.B., Stearns, V., Connolly, R.M., Velculescu, V.E.

Volltext

Multimodal measurement of glycocalyx degradation during coronary artery bypass grafting von Bol, Martine E, Huckriede, J B, van de Pas, K G H, Delhaas, T, Lorusso, R, Nicolaes, G A F, Sels, J E M, van de Poll, M C G

Volltext

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial von Ray-Coquard, I, Leary, A, Pignata, S, Cropet, C, Gonzalez-Martin, A, Marth, C, Nagao, S, Vergote, I, Colombo, N, Maenpaa, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E.M. Guerra, Bogner, G, Yoshida, H, Lefeuvre-Plesse, C, Buderath, P, Mosconi, A.M, Lortholary, A, Burges, A, Medioni, J, El-Balat, A, Rodrigues, M, Park-Simon, T.-W, Dubot, C, Denschlag, D, You, B, Pujade-Lauraine, E, Harter, P

Volltext

525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): St... von Makker, V., Colombo, N., Casado Herraez, A., Monk, B.J., Mackay, H., Santin, A.D., Miller, D.S., Moore, R.G., Baron-Hay, S.E., Ray-Coquard, I.L., Shapira-Frommer, R., Ushijima, K., Yonemori, K., Kim, Y.M., Guerra Alia, E.M., Sanli, U.A., Huang, J., McKenzie, J., Barresi, G., Lorusso, D.

Volltext

964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844) von Roussos Torres, E.T., Leatherman, J., Rafie, C., Brufsky, A., Lorusso, P., Eder, J.P., Chung, V., Yuan, Y., Downs, M., O’Connor, A., Piekarz, R., Streicher, H., Rudek, M.A., Zhu, Q., Fertig, E., Anders, R.A., Cimino-Mathews, A., Jaffee, E.M., Stearns, V., Connolly, R.M.

Volltext

Survival with Cemiplimab in Recurrent Cervical Cancer von Tewari, K.S, Monk, B.J, Vergote, I, Miller, A, de Melo, A.C, Kim, H.-S, Kim, Y.M, Lisyanskaya, A, Samouelian, V, Lorusso, D, Damian, F, Chang, C.-L, Gotovkin, E.A, Takahashi, S, Ramone, D, Pikiel, J, Mackowiak-Matejczyk, B, Alia, E.M. Guerra, Colombo, N, Makarova, Y, Rischin, D, Lheureux, S, Hasegawa, K, Fujiwara, K, Li, J, Jamil, S, Jankovic, V, Chen, C, Seebach, F, Weinreich, D.M, Yancopoulos, G.D, Lowy, I, Mathias, M, Fury, M.G, Oaknin, A

Volltext

Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment:... von O'Malley, D.M., Oza, A.M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J.I., Clamp, A.R., Scambia, G., Leary, A., Holloway, R.W., Gancedo, M. Amenedo, Fong, P.C., Goh, J.C., Armstrong, D.K., Banerjee, S., García-Donas, J., Swisher, E.M., Cameron, T., Maloney, L., Goble, S., Lin, K.K., Ledermann, J.A., Coleman, R.L.

Volltext

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer von Ray-Coquard, I, Pautier, P, Pignata, S, Perol, D, Gonzalez-Martin, A, Berger, R, Fujiwara, K, Vergote, I, Colombo, N, Maenpaa, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E.M. Guerra, Reinthaller, A, Nagao, S, Lefeuvre-Plesse, C, Canzler, U, Scambia, G, Lortholary, A, Marme, F, Combe, P, de Gregorio, N, Rodrigues, M, Buderath, P, Dubot, C, Burges, A, You, B, Pujade-Lauraine, E, Harter, P

Volltext

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinu... von Fujiwara, K., Harter, P., Leary, A., Perol, D., Pignata, S., González-Martín, A., Petru, E., van Nieuwenhuysen, E., Colombo, N., Mäenpää, J., Selle, F., de Gregorio, N., Lorusso, D., Guerra Alia, E.M., Lefeuvre-Plesse, C., Buderath, P., Lortholary, A., Burges, A., Pujade-Lauraine, E., Ray-Coquard, I.L.

Volltext

Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC von Mazzaschi, G., Madeddu, D., Veneziani, M., Sogni, F., Armani, G., Frati, C., Lagrasta, C., Falco, A., Lorusso, B., Vilella, R., Mangiaracina, C., Bocchialini, G., Silini, E.M., Facchinetti, F., Ardizzoni, A., Missale, G., Tiseo, M., Quaini, F.

Volltext

ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer von Kristeleit, R.S., Lorusso, D., Oaknin, A., Safra, T., Swisher, E.M., Bondarenko, I.M., Huzarski, T., Klat, J., Moiseyenko, V., Póka, R.L., Viola, L.S., Tankersley, C., Maloney, L., Goble, S., Unger, C., Dowson, A., Giordano, H., Oza, A.M.

Volltext

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO von Streng, Alexander S., Delnoij, Thijs S.R., Mulder, Mark M.G., Sels, Jan Willem E.M., Wetzels, Rick J.H., Verhezen, Paul W.M., Olie, Renske H., Kooman, Jeroen P., van Kuijk, Sander M.J., Brandts, Lloyd, ten Cate, Hugo, Lorusso, Roberto, van der Horst, Iwan C.C., van Bussel, Bas C.T., Henskens, Yvonne M.C.

Volltext